Physician profile
Kelsey Gray
NPI 1174660450
$5,124.35
in general payments reported to CMS, 2019-2025
24 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $575 · 2021: $538 · 2022: $462 · 2023: $901 · 2024: $555 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,089 · Travel and Lodging: $675 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,088.71 |
| Travel and Lodging | $674.58 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,184.53 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Intuitive Surgical, INC. | $674.58 | 2025 | |
| Genzyme Corporation | $389.52 | 2021-2025 | |
| Grifols USA, LLC | $242.97 | 2019-2024 | Prolastin-C Liquid |
| Medtronic, INC. | $220.93 | 2021-2025 | Illumisite |
| Astrazeneca Pharmaceuticals Lp | $177.25 | 2019-2025 | Airsupra, Breztri |
| Ethicon US, LLC | $165.07 | 2021-2025 | Surgiflo Hemostatic Matrix |
| Ambu INC. | $160.46 | 2023 | |
| Medtronic Vascular, INC. | $136.10 | 2020 | |
| Abbvie INC. | $133.85 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $84.81 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.63 | 2019-2025 | Ofev, Jascayd |
| Depuy Synthes Sales INC. | $75.27 | 2024 | Matrixrib |
| Philips North America LLC | $66.45 | 2019-2022 | |
| Medical Device Business Services, INC. | $65.68 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $53.90 | 2025 | Brinsupri, Arikayce |
| Verona Pharma, INC. | $39.22 | 2025 | Ohtuvayre |
| Abiomed | $31.08 | 2025 | |
| Sunovion Pharmaceuticals INC. | $28.68 | 2019 | |
| Mylan Specialty L.P. | $24.38 | 2024 | Yupelri |
| Amgen INC. | $24.27 | 2024 | Tezspire |
| Merck Sharp & Dohme LLC | $21.17 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.80 | 2023 | Austedo |
| Electromed, INC. | $20.75 | 2023 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.